Medpace Holdings, Inc. Proceeds from Lines of Credit
Medpace Holdings, Inc. (MEDP) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-02-10
- Medpace Holdings, Inc. proceeds from lines of credit for the quarter ending 2024-12-31 was $0.00.
- Medpace Holdings, Inc. proceeds from lines of credit for the quarter ending 2024-09-30 was $0.00.
- Medpace Holdings, Inc. proceeds from lines of credit for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Medpace Holdings, Inc. proceeds from lines of credit for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Medpace Holdings, Inc. proceeds from lines of credit for fiscal 2025 was $0.00.
- Medpace Holdings, Inc. proceeds from lines of credit for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Medpace Holdings, Inc. proceeds from lines of credit for fiscal 2023 was $105.00M, a 67.61% decline from fiscal 2022.
- Medpace Holdings, Inc. proceeds from lines of credit for fiscal 2022 was $324.20M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-10 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $0.00 derived: sum of 2 quarters · filed 2026-02-10 | $0.00 derived: sum of 3 quarters · filed 2026-02-10 | $0.00 10-K · filed 2026-02-10 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-22 | $0.00 derived: sum of 2 quarters · filed 2024-10-22 | $0.00 10-Q · filed 2024-10-22 | $0.00 derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-23 | $0.00 10-Q · filed 2024-07-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-10 | $0.00 derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $0.00 10-Q · filed 2024-04-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-10 | $0.00 derived: sum of 3 quarters · filed 2026-02-10 | $15.00M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $0.00 derived: sum of 2 quarters · filed 2026-02-10 | $15.00M derived: sum of 3 quarters · filed 2026-02-10 | $105.00M 10-K · filed 2026-02-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-22 | $15.00M derived: sum of 2 quarters · filed 2024-10-22 | $105.00M 10-Q · filed 2024-10-22 | $130.00M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-23 | $105.00M 10-Q · filed 2024-07-23 | $130.00M derived: sum of 3 quarters · filed 2025-02-11 | $130.00M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $90.00M 10-Q · filed 2024-04-23 | $115.00M derived: sum of 2 quarters · filed 2025-02-11 | $115.00M derived: sum of 3 quarters · filed 2025-02-11 | $364.70M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $25.00M derived: sum of 2 quarters · filed 2025-02-11 | $274.70M derived: sum of 3 quarters · filed 2025-02-11 | $324.20M 10-K · filed 2025-02-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-24 | $249.70M derived: sum of 2 quarters · filed 2023-10-24 | $299.20M 10-Q · filed 2023-10-24 | $299.20M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $249.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | $299.20M 10-Q · filed 2023-07-25 | $299.20M derived: sum of 3 quarters · filed 2024-02-13 | |
| 2022-03-31 | $49.50M 10-Q · filed 2023-04-25 | $49.50M derived: sum of 2 quarters · filed 2024-02-13 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $0.00 10-K · filed 2024-02-13 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-10-25 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-14 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 10-K · filed 2020-02-25 | ||
| 2018-09-30 | $0.00 10-Q · filed 2018-10-30 | |||
| 2017-12-31 | $60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $100.00M 10-K · filed 2020-02-25 | ||
| 2017-09-30 | $40.00M 10-Q · filed 2018-10-30 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $0.00 10-K · filed 2019-02-26 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-10-31 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-27 | |||
| 2014-12-31 | $1.57M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |